Table 3.
Serum biochemical parameters measured in each group throughout the study period.
| Groups | AST (U/L) |
CK (U/L) |
CK-MB (U/L) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| d0 | d15 | d90 | d180 | d0 | d15 | d90 | d180 | d0 | d15 | d90 | d180 | |
| NI_S_AP | 98.25 ± 54.52 | 90.86 ± 28.45 | 171.86 ± 159.89 | 109.20 ± 29.36 | 771.27 ± 836.11 | 302.90 ± 205.02 | 619.75 ± 463.06 | 795.12 ± 566.73 | 525.48 ± 208.80 | 439.14 ± 175.42 | 530.96 ± 188.02 | 486.22 ± 115.98 |
| NI_Epo_AP | 72.0 ± 21.0 | 85.80 ± 31.51 | 117.60 ± 68.85 | 100.20 ± 17.18 | 220.0 ± 176.06a | 292.08 ± 322.15 ab | 802.44 ± 802.02b | 615.36 ± 124.92b | 402.00 | 293.16 ± 63.82 | 376.05 ± 163.74 | 232.62 ± 51.22 |
| I_S_AP | 106.5 ± 35.45a | 184.20 ± 66.53b | 215.25 ± 64.50b | 186.0 ± 56.88b | 334.58 ± 210.66 ab | 315.36 ± 175.19a | 1053.53 ± 749.68b | 544.74 ± 454.28 ab | 421.73 ± 236.08 | 320.40 ± 65.52 | 687.53 ± 216.22 | 373.65 ± 151.22 |
| I_Epo_AP | 74.50 ± 22.64a | 251.14 ± 64.43c | 152.14 ± 41.77b | 180.0 ± 60.97b | 159.90 ± 102.63a | 663.75 ± 312.88c | 292.60 ± 129.65 ab | 366.30 ± 187.56b | 245.94 ± 72.13a | 413.40 ± 96.16bc | 350.23 ± 90.08 ab | 531.00 ± 123.66c |
| NI_S_CP | 113.63 ± 24.97b | 74.14 ± 22.89a | 162.86 ± 97.81b | 102.75 ± 9.60b | 253.75 ± 117.06 | 190.54 ± 80.91 | 710.96 ± 818.24 | 282.90 ± 82.74 | 382.44 ± 119.41a | 269.70 ± 152.99a | 378.25 ± 131.93a | 628.50 ± 36.73b |
| NI_Epo_CP | 95.25 ± 38.45 | 73.20 ± 18.07 | 121.8 ± 96.50 | 144.60 ± 95.92 | 690.48 ± 904.58b | 170.28 ± 77.51a | 732.30 ± 922.05b | 892.62 ± 746.68b | 481.05 ± 67.00b | 277.38 ± 107.59a | 341.70 ± 250.15 ab | 214.64 ± 59.20a |
| I_S_CP | 87.0 ± 16.43a | 234.60 ± 94.90b | 159.75 ± 38.76b | 171.6 ± 68.78b | 228.15 ± 115.83 | 592.50 ± 606.49 | 380.48 ± 198.93 | 252.54 ± 87.68 | 439.40 ± 299.08 | 339.23 ± 115.22 | 358.10 ± 202.01 | 198.50 ± 106.88 |
| I_Epo_CP | 90.43 ± 14.43a | 200.57 ± 33.52c | 131.63 ± 21.24b | 190.13 ± 41.47c | 276.73 ± 98.55 | 240.26 ± 92.39 | 348.56 ± 200.93 | 293.13 ± 193.74 | 455.49 ± 133.58b | 429.75 ± 59.28 ab | 302.40 ± 81.19a | 287.69 ± 152.21a |
Values are means ± standard deviation.
Different lower-case letters in the same row within the same variable are significantly different (p ≤ 0.05).
AST: aspartate aminotransferase. CK: the total creatine kinase. CK-MB: creatine kinase myocardial band. d: day experimental (0–180). NI_S_AP: uninfected and treated with saline between d1 and d30. NI_Epo_AP: uninfected and treated with erythropoietin (Epo) between d1 and d30. I_S_AP: infected with T. cruzi and treated with saline in the acute phase (d1 to d30). I_Epo_AP: infected and treated with Epo in the acute phase. NI_S_CP: uninfected and treated with saline between d90 and d120. NI_Epo_CP: uninfected and treated with Epo between d90 and d120. I_S_CP: infected with T. cruzi and treated with saline in the chronic phase (d90 to d120). I_Epo_CP: infected and treated with Epo in the chronic phase.